Clinical efficacy of romosozumab in the treatment of elderly male patients of osteoporotic with hip fractures: a retrospective study
Background: This study aims to evaluate the efficacy and safety of romosozumab in elderly male patients with osteoporosis-associated hip fractures. Methods: A retrospective analysis was conducted using medical records from 94 elderly male patients with hip fractures who received treatment at our...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MRE Press
2025-01-01
|
| Series: | Journal of Men's Health |
| Subjects: | |
| Online Access: | https://oss.jomh.org/files/article/20250124-473/pdf/JOMH2024083002.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Background: This study aims to evaluate the efficacy and safety of
romosozumab in elderly male patients with osteoporosis-associated hip fractures.
Methods: A retrospective analysis was conducted using medical records
from 94 elderly male patients with hip fractures who received treatment at our
institution between October 2021 and March 2023. The patients were divided into
two groups based on their treatment regimens: the observation group (n = 47)
received monthly subcutaneous injections of 210 mg romosozumab for 12 months, and
the control group (n = 47) was administered 10 mg of alendronate sodium orally
each morning. Results: The results showed that the total effective rate
was significantly higher in the observation group (p
< 0.05), with a marginally greater rate of significant effectiveness in the
observation group. Post-treatment assessments indicated significantly lower
Visual Analog Scale (VAS) and Oswestry Disability Index (ODI) scores in the
observation group than the control group (p < 0.05). Bone mineral
density (BMD) in the observation group was markedly higher, with significantly
reduced levels of osteocalcin (OSC) and bone-specific alkaline phosphatase (BALP)
(p < 0.05). Quality of life scores improved significantly in the
observation group (p < 0.05), and there was no significant difference
in adverse event incidence between the two groups (p > 0.05).
Follow-up evaluations at 3, 6 and 12 months revealed that the observation group
maintained higher BMD, osteocalcin, procollagen type 1 N-terminal propeptide
(P1NP), and C-terminal telopeptide of type 1 collagen (CTx) levels, alongside a
reduced incidence of fractures and adverse events compared to the control group
(p < 0.05). After one year, the fracture healing rate was
significantly higher in the observation group (p < 0.05).
Conclusions: These findings suggest that romosozumab
provides a substantial therapeutic benefit in
elderly male patients with osteoporotic hip fractures, with no notable increase
in adverse reactions and favorable follow-up outcomes. |
|---|---|
| ISSN: | 1875-6867 1875-6859 |